Business Context and Reporting Period
Company: Black Hawk Acquisition Corporation (Black Hawk)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended August 31, 2025
Business Overview: Black Hawk is a Cayman Islands exempted company formed as a "blank check" SPAC to effect a business combination. The Company has not commenced operations and generates no operating revenue. Its primary activity is identifying a target for an initial business combination. On April 26, 2025, the Company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., valued at a pre-money equity value of $70 million.
Key Financial Metrics
| Metric | As of/For Period Ended Aug 31, 2025 | As of/For Period Ended Nov 30, 2024 |
|---|---|---|
| Cash and Cash Equivalents | $15,000 | $264,842 |
| Investments in Trust Account | $23,296,572 | $71,829,264 |
| Total Assets | $23,341,102 | $72,143,335 |
| Total Liabilities | $3,361,168 | $2,485,978 |
| Working Capital Deficit | ($901,638) | N/A (Positive Working Capital) |
| Net Income (9 Months) | $1,333,322 | $1,164,002 |
| Net Income (3 Months) | $154,401 | $883,767 |
| Public Shares Outstanding | 2,124,077 | 6,900,000 |
Revenue: $0 (No operating revenue generated).
Expenses: General and administrative expenses for the nine months ended August 31, 2025, were $607,632, compared to $420,863 in the prior year period. Related party administrative fees were $90,000.
Debt: The Company has a convertible note payable to a related party (Sponsor) of $350,076 (including accrued interest) and a derivative liability of $2,140 associated with the conversion option.
Material Changes vs. Prior Period
- Significant Shareholder Redemptions: In connection with an Extraordinary General Meeting held in July 2025, holders of 4,775,923 public shares exercised redemption rights. Approximately $51.0 million was withdrawn from the Trust Account, reducing the balance from $71.8 million to $23.3 million.
- Extension of Combination Period: Shareholders approved an amendment to extend the deadline to consummate a business combination. The Company may now extend the deadline monthly through December 22, 2026, subject to a $150,000 monthly deposit into the Trust Account. Four extensions have been executed as of the filing date, extending the deadline to October 22, 2025.
- Liquidity Deterioration: Cash outside the Trust Account dropped from $264,842 to $15,000 due to operating expenses and redemption payments. The Company now reports a working capital deficit of $901,638.
- Related Party Financing: The Company issued a new convertible note to the Sponsor in June 2025 for up to $350,000 to fund working capital and extension fees. A subsequent convertible note was issued in September 2025 (subsequent event).
Outlook, Risks, and Management Commentary
Business Combination Status: The proposed transaction with Vesicor Therapeutics, Inc. is subject to regulatory approvals, shareholder votes, and Nasdaq listing approval. Management expects completion in the fourth quarter of 2025.
Going Concern: Management has determined that the Company's liquidity position and the uncertainty of completing a business combination raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from this uncertainty.
Internal Controls: Management concluded that disclosure controls and procedures were not effective as of August 31, 2025.
Risks:
- Failure to complete the business combination within the extended deadline could result in liquidation.
- Insufficient working capital outside the Trust Account to fund operations or transaction costs.
- Global economic uncertainties and geopolitical conflicts impacting the ability to consummate the transaction.
Investor Verification Checklist
- Redemption Impact: Verify the remaining cash in the Trust Account ($23.3M) is sufficient to cover the deferred underwriting fee ($2.4M) and the redemption value of remaining shares if the deal fails.
- Extension Funding: Confirm the Sponsor's ability and commitment to fund the $150,000 monthly extension payments required to maintain the deadline through December 2026.
- Transaction Closing: Monitor the status of shareholder approvals and regulatory clearances for the Vesicor Therapeutics merger, specifically the Q4 2025 closing target.
- Internal Controls: Review the specific material weaknesses identified in the internal control assessment that led to the "not effective" conclusion.
- Related Party Notes: Assess the terms of the convertible notes issued to the Sponsor and their potential dilution impact upon conversion.